Padeliporfin

Drug Profile

Padeliporfin

Alternative Names: Palladium bacteriopheophorbide; Pd-bacteriopheophorbide; Pd-Bpheid; Tookad; WST-09; WST09 cpd

Latest Information Update: 14 Jun 2010

Price : $50

At a glance

  • Originator STEBA France
  • Class Antineoplastics; Porphyrins; Small molecules
  • Mechanism of Action Photosensitisers; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 31 May 2006 Phase-II/III clinical trials in Prostate cancer in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top